BRPI0908154A2 - Métodos para o tratamento e a prevenção de disfunções retinianas relacionadas à idade - Google Patents

Métodos para o tratamento e a prevenção de disfunções retinianas relacionadas à idade

Info

Publication number
BRPI0908154A2
BRPI0908154A2 BRPI0908154-2A BRPI0908154A BRPI0908154A2 BR PI0908154 A2 BRPI0908154 A2 BR PI0908154A2 BR PI0908154 A BRPI0908154 A BR PI0908154A BR PI0908154 A2 BRPI0908154 A2 BR PI0908154A2
Authority
BR
Brazil
Prior art keywords
age
prevention
treatment
methods
related retinal
Prior art date
Application number
BRPI0908154-2A
Other languages
English (en)
Inventor
Tadao Maeda
David Saperstein
Krystof Palczewski
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of BRPI0908154A2 publication Critical patent/BRPI0908154A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0908154-2A 2008-02-11 2009-02-10 Métodos para o tratamento e a prevenção de disfunções retinianas relacionadas à idade BRPI0908154A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2762508P 2008-02-11 2008-02-11
PCT/US2009/000824 WO2009102418A1 (en) 2008-02-11 2009-02-10 Methods for the treatment and prevention of age-related retinal dysfunction

Publications (1)

Publication Number Publication Date
BRPI0908154A2 true BRPI0908154A2 (pt) 2015-08-11

Family

ID=40521846

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908154-2A BRPI0908154A2 (pt) 2008-02-11 2009-02-10 Métodos para o tratamento e a prevenção de disfunções retinianas relacionadas à idade

Country Status (14)

Country Link
US (7) US8324270B2 (pt)
EP (1) EP2252276B1 (pt)
JP (3) JP6022746B2 (pt)
KR (2) KR20160092032A (pt)
CN (1) CN101969938A (pt)
AU (1) AU2009213138B2 (pt)
BR (1) BRPI0908154A2 (pt)
CA (2) CA3018374A1 (pt)
IL (2) IL207220B (pt)
MX (1) MX337656B (pt)
NZ (3) NZ600498A (pt)
RU (1) RU2565448C2 (pt)
WO (1) WO2009102418A1 (pt)
ZA (1) ZA201005434B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040242704A1 (en) 2003-03-14 2004-12-02 University Of Washington, Techtransfer - Invention Licensing Stabilized mutant opsin proteins
NZ552080A (en) 2004-06-18 2011-03-31 Univ Washington 9-cis-retinyl esters and uses thereof
EP2336117A1 (en) 2005-05-26 2011-06-22 Neuron Systems, Inc Heterocyclic compounds for treating retinal diseases
MX337656B (es) 2008-02-11 2016-03-14 Univ Washington Metodos para el tratamiento y prevencion de disfuncion retinal relacionada con la edad.
MX2012003220A (es) 2009-09-15 2012-08-03 Quadra Logic Tech Inc Formulaciones farmaceuticas que comprenden 9-cis-retinil esteres en un vehiculo de lipido.
EP2509596B1 (en) 2009-12-08 2019-08-28 Case Western Reserve University Gamma aminoacids for treating ocular disorders
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
KR101851249B1 (ko) * 2010-04-19 2018-06-20 노벨리언 테라퓨틱스 인코포레이티드 내인성 레티노이드 결핍과 연관된 시각 장애의 치료 또는 완화를 위한 치료용 조성물, 제형 및 키트
US8846723B2 (en) 2010-07-29 2014-09-30 Eastman Chemical Company Esters of O-substituted hydroxy carboxylic acids and preparations thereof
US8613940B2 (en) 2010-09-03 2013-12-24 Eastman Chemical Company Carbonate derivatives as skin care
US8329938B2 (en) * 2011-02-21 2012-12-11 Eastman Chemical Company Hydroxyalkanoic acid and hydroxyalkanoice acid oligomer esters of retinol
WO2013082149A1 (en) * 2011-11-28 2013-06-06 Case Western Reserve University Polysaccharide therapeutic conjugates
KR102133608B1 (ko) * 2012-03-01 2020-07-13 레티나제닉스, 엘엘씨 내인성 레티노이드 결핍증과 관련된 시각 장애에서 시각 기능의 개선을 위한 치료 요법 및 방법
CA2898631C (en) 2013-01-23 2023-06-13 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
WO2015184453A1 (en) 2014-05-30 2015-12-03 Case Western Reserve University Retinylamine derivitives for treatment of ocular disorders
US11129845B2 (en) 2014-06-18 2021-09-28 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
US10925980B2 (en) 2014-08-04 2021-02-23 Case Western Reserve University Molecular probes and methods of use
US11407786B2 (en) 2015-06-18 2022-08-09 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
CN108135907A (zh) 2015-08-21 2018-06-08 奥尔德拉医疗公司 氘化化合物和其用途
US12060318B2 (en) 2015-10-09 2024-08-13 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
US11129823B2 (en) 2016-05-09 2021-09-28 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
US10414732B2 (en) 2017-03-16 2019-09-17 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
MX2020003425A (es) 2017-10-10 2020-07-29 Aldeyra Therapeutics Inc Tratamiento de trastornos inflamatorios.
EP3833660A4 (en) 2018-08-06 2022-05-11 Aldeyra Therapeutics, Inc. POLYMORPHIC COMPOUNDS AND THEIR USES
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CA3137301A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2021062022A1 (en) * 2019-09-25 2021-04-01 The Board Of Trustees Of The Leland Stanford Junior University Metabolic rescue of retinal degeneration
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
CA3178762A1 (en) * 2020-06-09 2021-12-16 Eluminex Biosciences (Suzhou) Limited Methods of treating visual disorders using daily low dosing of a retinoid compound

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3196076A (en) 1961-12-20 1965-07-20 Schering Corp Anti-depressant 10-(3-dimethylaminopropyl)-3-azaphenothiazine
US3196078A (en) * 1962-01-30 1965-07-20 Ortho Pharma Corp Process for combating retinits pigmentosa
US3517067A (en) * 1964-02-11 1970-06-23 Eastman Kodak Co Syntheses of quaternary phosphonium salts
DE2300107C2 (de) 1973-01-03 1982-03-11 Basf Ag, 6700 Ludwigshafen Vitamin A-Säureanilid-4-carbonsäureäthylester, Verfahren zu seiner Herstellung und diesen enthaltende Zubereitungen
DE2456959A1 (de) 1974-12-03 1976-06-16 Basf Ag 4-(e)- und 4-(z)-7-methyl-9-(2,6,6trimethyl-1-cyclohexen-1-yl)-nona-2,4,6,8tetraencarbonsaeure, ihre derivate und diese enthaltende zubereitungen
JPS61275266A (ja) 1985-05-28 1986-12-05 Taisho Pharmaceut Co Ltd レチノイド誘導体
US5310764A (en) * 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene
JPH06340525A (ja) 1993-06-02 1994-12-13 Lion Corp 安定な低眼刺激性ビタミンａ類可溶化点眼剤
NZ283658A (en) 1994-04-04 1999-09-29 William R Freeman Compositions and treatment of increased intraocular pressure with phosphonyl-alkyloxy-pyrimidines/purines (nucleosides)
RU2106843C1 (ru) 1994-06-29 1998-03-20 Красноярская государственная медицинская академия Способ лечения близорукости
JPH08198746A (ja) 1995-01-18 1996-08-06 Lion Corp 可溶化点眼剤
US5837728A (en) * 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
US5489611A (en) 1995-02-10 1996-02-06 Warner-Lambert Company Method for lowering plasma levels of lipoprotein (a)
US5620970A (en) * 1995-06-05 1997-04-15 Alcon Laboratories, Inc. Topical ophthalmic carbonic anhydrase inhibitor formulations
US5716627A (en) 1996-04-25 1998-02-10 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester
EP0908179A1 (en) 1997-08-23 1999-04-14 Werner Bollag Treatment of cell-mediated immune diseases
US6391924B1 (en) * 1997-12-10 2002-05-21 Hampar Karageozian Taurine derivatives useable in the treatment of ophthalmic disorders
US6552009B2 (en) * 1998-07-16 2003-04-22 Gentrix Llc Compositions and methods of treating abnormal cell proliferation
US6372463B1 (en) 1999-05-06 2002-04-16 The President & Fellows Of Harvard College Mutations in nucleic acid molecules encoding 11-CIS retinol dehydrogenase, the mutated proteins, and uses thereof
WO2000068354A1 (en) 1999-05-07 2000-11-16 Chemlink Laboratories Llc Window cleaner tablet
US6300328B1 (en) * 1999-08-06 2001-10-09 Alcon Universal Ltd. Selective inhibitors of adenosine monophosphate deaminase for the treatment of optic nerve and retinal damage
US20020028849A1 (en) * 2000-04-18 2002-03-07 Godkin James D. Use of retinol in assisted-reproduction protocols
US6696069B2 (en) * 2000-06-30 2004-02-24 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Skin care cosmetic compositions containing phosphates and/or sulfates of branched alcohols and/or ethoxylates thereof
US7030265B2 (en) 2001-01-11 2006-04-18 Chebigen, Inc. Retinol derivatives, the method of preparations and the uses thereof
AU2002240141A1 (en) 2001-01-26 2002-08-06 Steven Baranowitz Systemic formulations containing beta-carotene and derivatives thereof
GB0103998D0 (en) 2001-02-19 2001-04-04 King S College London Method
WO2002082904A2 (en) * 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
WO2003059336A1 (en) 2002-01-18 2003-07-24 Tatton Technologies, Llc. Methods for treating eye disorders
US20030215413A1 (en) * 2002-03-22 2003-11-20 L'oreal Compositions containing stabilized retinoid
US20040097587A1 (en) * 2002-03-27 2004-05-20 Arbiser Jack L Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
KR20040095250A (ko) * 2002-03-29 2004-11-12 맥심 파마수티컬즈 인크. 안내 손상의 치료 및 예방에 사용하기 위한 활성 산소대사물(ｒｏｍ)의 생성 및 방출 억제제의 용도
US20040242704A1 (en) 2003-03-14 2004-12-02 University Of Washington, Techtransfer - Invention Licensing Stabilized mutant opsin proteins
US7566808B2 (en) 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
JP2007525496A (ja) * 2004-02-17 2007-09-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 黄班変性症を含む眼科疾患の管理
AU2005215778B2 (en) * 2004-02-17 2009-03-12 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
US9421175B2 (en) 2004-03-17 2016-08-23 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
NZ552080A (en) 2004-06-18 2011-03-31 Univ Washington 9-cis-retinyl esters and uses thereof
KR100862930B1 (ko) * 2004-06-23 2008-10-13 시리온 테라퓨틱스, 인크. 레티닐 유도체를 사용하여 안 증상을 치료하기 위한 방법및 조성물
JP2008515778A (ja) * 2004-08-18 2008-05-15 シリオン セラピューティクス， インコーポレイテッド 眼の状態を１３−シス−レチニル誘導体で処置するための組み合わせ方法、組成物および治療
WO2006039551A2 (en) * 2004-09-30 2006-04-13 The Regents Of The University Of California Local administration of retinoids to treat deficiencies in dark adaptation
EP2687208A1 (en) * 2007-09-12 2014-01-22 The Trustees of Columbia University in the City of New York Compositions and Methods for Treating Macular Degeneration
MX337656B (es) * 2008-02-11 2016-03-14 Univ Washington Metodos para el tratamiento y prevencion de disfuncion retinal relacionada con la edad.

Also Published As

Publication number Publication date
JP2016190852A (ja) 2016-11-10
JP2014221828A (ja) 2014-11-27
JP6272943B2 (ja) 2018-01-31
RU2565448C2 (ru) 2015-10-20
US8324270B2 (en) 2012-12-04
US20100035986A1 (en) 2010-02-11
KR20160092032A (ko) 2016-08-03
EP2252276B1 (en) 2019-03-27
US20160331713A1 (en) 2016-11-17
KR101810381B1 (ko) 2017-12-19
IL207220B (en) 2018-04-30
NZ617701A (en) 2015-06-26
CA2714530C (en) 2018-09-25
EP2252276A1 (en) 2010-11-24
CA2714530A1 (en) 2009-08-20
MX337656B (es) 2016-03-14
ZA201005434B (en) 2011-11-30
RU2010137842A (ru) 2012-03-20
AU2009213138B2 (en) 2014-11-06
US20130072561A1 (en) 2013-03-21
AU2009213138A1 (en) 2009-08-20
US20190133986A1 (en) 2019-05-09
US9408821B2 (en) 2016-08-09
CN101969938A (zh) 2011-02-09
MX2010008847A (es) 2010-11-30
US9855239B2 (en) 2018-01-02
JP6022746B2 (ja) 2016-11-09
NZ587376A (en) 2012-06-29
US9233091B2 (en) 2016-01-12
JP2011511789A (ja) 2011-04-14
IL258356A (en) 2018-05-31
WO2009102418A1 (en) 2009-08-20
KR20100126358A (ko) 2010-12-01
IL207220A0 (en) 2010-12-30
JP5934304B2 (ja) 2016-06-15
CA3018374A1 (en) 2009-08-20
US20180098955A1 (en) 2018-04-12
NZ600498A (en) 2014-01-31
US20130072557A1 (en) 2013-03-21
US20130072558A1 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
PT2520295T (pt) Métodos para prevenir e tratar a mucosite
BRPI0919920A2 (pt) compostos para tratamento de doenças e desordens oftálmicas
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
PT2894165T (pt) Métodos e composições para o tratamento de distúrbios associados ao complemento
BR112013018754A2 (pt) combinação de componentes para a prevenção e tratamento de fragilidade
PT2367561E (pt) Composições e métodos para o tratamento da doença celíaca
BRPI0817612A2 (pt) Aparelho para tratamento dos cabelos a vapor
BR112012004167A2 (pt) métodos para a prevenção e o tratamento de isquemia cerebral
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
PL2172212T3 (pl) Nowatorska immunoterapia przeciwko szeregowi guzów włączając guzy neuronowe i guzy mózgu
HUE049880T2 (hu) Anyag és eljárások Her-3-mal összefüggõ betegségek kezelésére vagy megelõzésére
BRPI0810561A2 (pt) métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13.
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
BRPI0810525A2 (pt) Composições e métodos para a profilaxia e tratamento de dependência química
BRPI0811752A2 (pt) Aparelho para tratar gás
BRPI0919288A2 (pt) teriapia de combinação para tratamento de diabetes e condições relacionadas.
BRPI0813621A2 (pt) imunoterapia contra tumores neuronais e cerebrais
BRPI0813498A2 (pt) Aparelho e métodos para fixar um prendedor
BRPI0917567A2 (pt) tratamento de doença respiratória
BRPI0813670A2 (pt) Compostos para tratamento
DE602008004368D1 (de) Endoskop-Behandlungswerkzeug
BRPI0911083A2 (pt) métodos para o tratamento ou prenvenção de diabetes mullitus e outros desequilíbrios metabólicos
BRPI0811930A2 (pt) Métodos e composições para a identificação e o tratamento de lúpus
BRPI0811870A2 (pt) Tratamento e prevenção de influenza

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]